Biogen strikes deal with Isis to develop drugs for ALS, other diseases
This article was originally published in Scrip
Biogen Idec is paying $100 million to Isis Pharmaceuticals in a collaborative effort to develop treatments for neurological diseases, such as ALS.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.